Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay

Thrombosis Research

Volumn 86, Issue 5, 1997, Pages 373-383

  Pötzsch, Bernd ^a   Hund, Simone ^a   Madlener, Katharina ^a   Unkrig, Christoph ^b   Müller Berghaus, Gert ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Ecarin clotting time; R hirudin; Systemic anticoagulation

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; ECARIN; FIBRINOGEN; HEPARIN; LEPIRUDIN; MEIZOTHROMBIN; PHENPROCOUMON; PROTHROMBIN;

ACCURACY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION TESTS; ENDOPEPTIDASES; FIBRINOGEN; HIRUDINS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; RECOMBINANT PROTEINS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SAFETY;

EID: 0343376125     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00082-0     Document Type: Article

References (15)

1. VAN DEN BOS AA, DECKERS JW, HEYNDRICKX GR, LAARMA GJ, SURYAPRANATA H, ZIJLSTRA F, CLOSE P, RIJNIERSE JJMM, BULLER HR, SERRUYS PW. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88, 58-66, 1993.
2. ZOLHEL YI P, WEBSTER MWI, FUSTER V, GRILL DE, GASPAR D, EDWARDS SJ, CABOT CF, CHESEBRO JH. Recombinant hirudin in patients with chronic, stable coronary artery disease - safety, half-life, and effect on coagulation parameters. Circulation 88, 2015-2022, 1993.
3. The Global Use of Strategies to Open Occluded Arteries (Gusto) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Eng J Med 335, 775-781, 1996.
4. GREINACHER A, VÖLPEL H, PÖTZSCH B. Recombinant hirudin in the treatment of patients with heparin-associated thrombocytopenia type II (HAT). [Abstract] Annals of Hematology 72, A92, 1996.
5. ANTMAN EM. Hirudin in acute myocardial infarction - Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90, 1624-1630, 1994.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIA Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90, 1631-1637, 1994.
7. NEUHAUS KL, ESSEN VR, TEBBE U, JESSEL A, HEINRICHS H, MÄURER W, DÖRONG W, HARMJANZ D, KÖTTER V, KALHAMMER E, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study - A study of the Arbeitsgemeinschaft leitender kardiologischer Krankenhausärzte (ALKK). Circulation 90, 1638-1642, 1994.
8. VERSTRAETE M, NURMOHAMED M, KIENAST J, SIEBECK M, SILLING-ENGELHARDT G, BÜLLER H, HORT B, BICHLER J, CLOSE P. Biological effects of recombinant hirudin (CGP 39393) in human volunteers. JACC 22, 1080-1088, 1993.
9. NURMOHAMED MT, BERCKMANS RJ, MORRIEN-SALOMONS WM, BERENDS F, HAMMES WD, RIJNIERSE JJMM, STURK A. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost 72, 685-692, 1992.
10. HAFNER G, FICKENSCHER K, FRIESEN HJ, RUPPRECHT HJ, KONHEISER U, EHRENTHAL W, LOTZ J, PRELLWITZ W. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 77, 165-173, 1995.
11. NOWAK G and BUCHA E. A new method for the therapeutical monitoring of hirudin. [Abstract] Thromb Haemost 69, 1306, 1993.
12. NOWAK G and BUCHA E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemostas 22, 197-202, 1996.
13. NOVOA E and SEEGERS WH. Mechanisms of alpha-thrombin and beta-thrombin-E formation: use of ecarin for isolation of meizothrombin 1. Thromb Res 18, 657-668, 1980.
14. ZEYMER U and NEUHAUS KL. Hirudin and excess bleeding - implications for future use. Drug Safety 12, 234-239, 1995.
15. SOLANO C, COBCROFT G, SCOTT DC. Prediction of vitamin K response using the echis time and echis-prothrombin time ratio. Thromb Haemost 64, 353-357, 1990.